NIKKEI 225
37,552.16 +113.55 (+0.30%) HANG SENG
16,828.93 +317.24 (+1.92%) CRUDE OIL
83.44 +0.08 (+0.10%) GOLD FUTURES
2,335.70 -6.40 (-0.27%) DOW
38,503.69 +263.71 (+0.69%) Bitcoin GBP
53,248.81 -660.70 (-1.23%)
Sanofi (0O59.IL)
| Previous close | 88.05 |
| Open | 88.42 |
| Bid | 87.87 x 0 |
| Ask | 89.66 x 0 |
| Day's range | 87.64 - 88.97 |
| 52-week range | 80.62 - 105.14 |
| Volume | |
| Avg. volume | 1,368,109 |
| Market cap | 117.081B |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | 12.96 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.56 (3.60%) |
| Ex-dividend date | 30 May 2023 |
| 1y target est | N/A |
- GlobeNewswire
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential of rilzabrutinib to provide a clinically meaningful benefit to patients living with ITPRegulatory submissions in the US and EU anticipated by year-endRilzabrutinib is one of 12 potential medicines and vaccines in Sanofi’s robust immunology pipeline and a testament to Sanofi’s ability to successfully accele
- GlobeNewswire
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a potential first-in-class, high-efficacy, non-lymphocyte depleting treatment for relapsing multiple sclerosis96% of participants receiving high-dose intravenous frexalimab had no new Gd+ T1 lesions and an annualized relapse rate of 0.04 after 48 weeksSanofi has initiated global phase 3 studies of frexalimab in relapsing MS and non-relapsing secondary progressive MS
- GlobeNewswire
Sanofi: Information concerning the total number of voting rights and shares - March 2024
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,529,599,938 €Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regi
